A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
Hematopathologic Correlates of CAR T-Cell Therapy
2021
Clinics in Laboratory Medicine
Preserved Fulltext
CD19-targeting chimeric antigen rector (CAR) T-cell products are used for the treatment of relapsed/refractory B-acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and mantle cell lymphoma. The success of CD19-CAR-T cells has led to the investigation of CAR T-cell products targeting different antigens in other hematological malignancies and solid tumors. Clinical laboratories play an important role in the manufacture, distribution, and monitoring of CAR T-cell therapy. Hence, it is
doi:10.1016/j.cll.2021.03.012
pmid:34304768
fatcat:5fntsbfoy5h4vdv4o75j5a35zq